SERB Pharmaceuticals Acquires Vistogard and Xuriden from Wellstat Therapeutics

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Vistagen Acquires Pherin Pharmaceuticals

December 21, 2022

Biotechnology

Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

Medix Biochemica Acquires ViroStat LLC

November 10, 2023

Biotechnology

Medix Biochemica has acquired 100% of ViroStat LLC, a US-based manufacturer of infectious disease antibodies and antigens, expanding Medix's IVD raw materials portfolio and scientific capabilities. ViroStat will continue operating in Westbrook, Maine, and its employees and leadership (including President Dr. Douglas McAllister and General Manager Duncan McAllister) will join Medix Biochemica.

The Vistria Group Acquires BioCare, Inc.

November 8, 2021

Healthcare Services

The Vistria Group has acquired BioCare, Inc., a Tempe-based specialty pharmaceutical distributor, specialty pharmacy and pharmaceutical logistics provider. The deal is Vistria’s first investment from its $2.68 billion Fund IV and aims to support BioCare’s growth — both organically and via acquisitions — to expand access to therapies for rare and orphan diseases.

Idera Pharmaceuticals Acquires Aceragen

September 28, 2022

Biotechnology

Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.